Skip to main content
Top

Cellular Oncology

Issue 2/2015

Content (7 Articles)

Review

Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis

Mohammad Shahjahani, Javad Mohammadiasl, Fatemeh Noroozi, Mohammad Seghatoleslami, Saeid Shahrabi, Fakhredin Saba, Najmaldin Saki

Original Paper

Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway

Jin Ju Park, Su Jung Hwang, Ji-Hyeon Park, Hyo-Jong Lee

Open Access Original Paper

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, Richard J. Honeywell, Henk Dekker, Dennis Poel, Kaamar Azijli, Godefridus J. Peters, Henk J. Broxterman, Henk M. W. Verheul

Open Access Original Paper

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

Armin Maier, Anne-Lise Peille, Vincent Vuaroqueaux, Michael Lahn

Original Paper

Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients

Stoyan Naidenov Bichev, Dora Marinova Marinova, Yanina Georgieva Slavova, Alexey Slavkov Savov

Original Paper

Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes

Vassilis Papanikolaou, Nikolaos Stefanou, Stephanie Dubos, Ioanna Papathanasiou, Maria Palianopoulou, Vaia Valiakou, Aspasia Tsezou

Original Paper

Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report

Hui Peng, Jun Huang, Ying Hu, Yisheng Wei, Huanliang Liu, Meijin Huang, Lei Wang, Jianping Wang

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine